Inflammatory reaction in patients with acquired bronchiectasis based on the interleukin 1α and interleukin 10 levels measured using the ELISA method

1Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Caraluna JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128: 739–745.Martinez-GarciaMAPerpina-TorderaMRoman-SanchezPSoler-CaralunaJJQuality-of-life determinants in patients with clinically stable bronchiectasisChest200512873974510.1378/chest.128.2.73916100162Search in Google Scholar

2Smith MP. Non-cystic fibrosis bronchiectasis. The Journal of Royal College of Physicians of Edinburgh. 2011;41: 132–139; quiz 139.SmithMPNon-cystic fibrosis bronchiectasisThe Journal of Royal College of Physicians of Edinburgh201141132139quiz 139.10.4997/JRCPE.2011.21721677919Search in Google Scholar

3Barker AF. Bronchiectasis. The New England Journal of Medicine. 2002;246: 1383–1393.BarkerAFBronchiectasisThe New England Journal of Medicine20022461383139310.1016/B978-032304825-5.10033-9Search in Google Scholar

4Chalmers JD, Smith MP, McHugh BI, Doherty C, Govan JR, Hill AT. Shrt- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012:186: 657–665.ChalmersJDSmithMPMcHughBIDohertyCGovanJRHillATShrt- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasisAmerican Journal of Respiratory and Critical Care Medicine201218665766510.1164/rccm.201203-0487OC22744718Search in Google Scholar

5Loeinger MR, Wells AU, Hansell DM, Chinyanganya N, Devajan A., Meister M, et al. Mortality in bronchectasis: A long term study assessing the factors influencing survival. European Respiratory Journal. 2009;34: 843–849.LoeingerMRWellsAUHansellDMChinyanganyaNDevajanA.MeisterMMortality in bronchectasis: A long term study assessing the factors influencing survivalEuropean Respiratory Journal20093484384910.1183/09031936.0000370919357155Search in Google Scholar

6Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmission, mortality and acute exacerbation of bronchiectasis. Internal Medicine Journal. 2012;42: e129–e136.RobertsMELowndesLMilneDGWongCASocioeconomic deprivation, readmission, mortality and acute exacerbation of bronchiectasisInternal Medicine Journal201242e129e13610.1111/j.1445-5994.2011.02444.x21299784Search in Google Scholar

7Pasteru MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline non-CF bronchiectasis. Thorax. 2010;65(Suppl. 1): 11–58.PasteruMCBiltonDHillATBritish Thoracic Society Bronchiectasis non-CF Guideline GroupBritish Thoracic Society guideline non-CF bronchiectasisThorax201065Suppl. 1115810.1136/thx.2010.14277820627912Search in Google Scholar

8Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine. 2005;12: 205–209.WeyckerDEdelsbergJOsterGTinoGPrevalence and economic burden of bronchiectasisClinical Pulmonary Medicine20051220520910.1097/01.cpm.0000171422.98696.edSearch in Google Scholar

9King P, Holds Worth S, Freezer N, Holmes P. Bronchiectasis. Internal Medicine Journal. 2006;36: 729–737.KingPHolds WorthSFreezerNHolmesPBronchiectasisInternal Medicine Journal20063672973710.1111/j.1445-5994.2006.01219.x17040360Search in Google Scholar

10Cumbaia AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory IM, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine. 2005;4: 117–122.CumbaiaAAEdmondsLCBauerMAJederlinicPJMayJJVictoryIMThe disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasisTreatments in Respiratory Medicine2005411712210.2165/00151829-200504020-0000515813663Search in Google Scholar

11Crosbie PAJ, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. European Respiratory Journal. 2009;33: 171–181.CrosbiePAJWoodheadMALong-term macrolide therapy in chronic inflammatory airway diseasesEuropean Respiratory Journal20093317118110.1183/09031936.0004220819118228Search in Google Scholar

12Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. American Journal of Respiratory and Critical Care Medicine. 1998;157(6 pt 1): 1829–1832.KudohSAzumaAYamamotoMIzumiTAndoMImprovement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycinAmerican Journal of Respiratory and Critical Care Medicine19981576 pt 11829183210.1164/ajrccm.157.6.97100759620913Search in Google Scholar

13Serieri DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respiratory Medicine. 2011;105: 946–949.SerieriDJMartinMLLong-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbationsRespiratory Medicine201110594694910.1016/j.rmed.2011.01.00921367595Search in Google Scholar

14Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;138: 1202–1212.FriedlanderALAlbertRKChronic macrolide therapy in inflammatory airways diseasesChest20101381202121210.1378/chest.10-019621051396Search in Google Scholar

15Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, MAltezos E, Zarogoulidis K. Macrolides from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. European Journal of Clinical Pharmacology. 2012l;68: 479–503.ZarogoulidisPPapanasNKioumisIChatzakiEMaltezosEZarogoulidisKMacrolides from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseasesEuropean Journal of Clinical Pharmacology20126847950310.1007/s00228-011-1161-x22105373Search in Google Scholar

16Boyton JR, Altmann DM. Bronchiectasis: Current concepts in pathogenesis, immunology, and microbiology. Annual Reviews of Pathology: Mechanisms if Disease, 2016;11: 523–554. [https://www.annualreviews.org/doi/10.1146/annurev-pathol-012615-044344 accessed online on 23.06.2018].BoytonJRAltmannDMBronchiectasis: Current concepts in pathogenesis, immunology, and microbiologyAnnual Reviews of Pathology: Mechanisms if Disease201611523554[https://www.annualreviews.org/doi/10.1146/annurev-pathol-012615-044344 accessed online on 23.06.2018].10.1146/annurev-pathol-012615-04434426980162Search in Google Scholar

17Ho JC, Tipoe G, et al, In vitro study of regulation on IL-6 production in bronchiectasis. Respiratory Medicine. 2014;98(4): 334–341.HoJCTipoeGIn vitro study of regulation on IL-6 production in bronchiectasisRespiratory Medicine201498433434110.1016/j.rmed.2003.10.01215072174Search in Google Scholar

18Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections. Advances in Experimental Medicine and Biology. 2013;783: 121–140.TorradoECooperAMCytokines in the balance of protection and pathology during mycobacterial infectionsAdvances in Experimental Medicine and Biology201378312114010.1007/978-1-4614-6111-1_7377350623468107Search in Google Scholar

19King TP. The role of the immune response in the pathogenesis of bronchiectasis. BioMed Research International. 2018;2018: 12.KingTPThe role of the immune response in the pathogenesis of bronchiectasisBioMed Research International201820181210.1155/2018/6802637587890729744361Search in Google Scholar

20Andrei L, Milena AM, Roxana MN, Tudor H, Ioan ST, Beatrice MB, et al. Serum interleukin 4 and 6 levels measured using the ELISA method in patients with acquired bronchiectasis compared to healthy subjects. An anti-inflammatory and pro-inflammatory relation. Revista de Chimie. 2019;70: 2411–2414.AndreiLMilenaAMRoxanaMNTudorHIoanSTBeatriceMBSerum interleukin 4 and 6 levels measured using the ELISA method in patients with acquired bronchiectasis compared to healthy subjects. An anti-inflammatory and pro-inflammatory relationRevista de Chimie2019702411241410.37358/RC.19.7.7351Search in Google Scholar

21Zhu J, Qiu Y, Valobra M, Qiu S, Majumdar S, Matin D, De Rose V, Jeffery PK. Plasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2007;175(11): 1125–1133.ZhuJQiuYValobraMQiuSMajumdarSMatinDDe RoseVJefferyPKPlasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary diseaseAmerican Journal of Respiratory and Critical Care Medicine2007175111125113310.1164/rccm.200602-161OC17322111Search in Google Scholar

22Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat, JJ, Kotz D, Passos VL, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: A case-control study. BMC Medical Genetics. 2009;10: 23.YanbaevaDGDentenerMASpruitMAHouwing-DuistermaatJJKotzDPassosVLIL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: A case-control studyBMC Medical Genetics2009102310.1186/1471-2350-10-23266030119272152Search in Google Scholar

23Nitescu M, Furtunescu FL, Otelea M, Rafila A, Streinu-Cercel A. Prevalence of metabolic syndrome parameters in a Romanian population of young adults. Revista Romana de Medicina de Laborator. 2012;20(3): 21–28.NitescuMFurtunescuFLOteleaMRafilaAStreinu-CercelAPrevalence of metabolic syndrome parameters in a Romanian population of young adultsRevista Romana de Medicina de Laborator20122032128Search in Google Scholar

24Miotto D, Ruggieri MP, Boschetto P, Cavallesco G, Papi A, Bononi I, et al. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. European Respiratory Journal. 2003;22(4): 602–608.MiottoDRuggieriMPBoschettoPCavallescoGPapiABononiIInterleukin-13 and -4 expression in the central airways of smokers with chronic bronchitisEuropean Respiratory Journal200322460260810.1183/09031936.03.0004640214582911Search in Google Scholar

25De Moraes MR, Da Costa AC, Correa Kde S, Junqueira-Kipnis AP, Rabahi MF. Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2014;9: 735–743.De MoraesMRDa CostaACCorrea KdeSJunqueira-KipnisAPRabahiMFInterleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPDInternational Journal of Chronic Obstructive Pulmonary Disease2014973574310.2147/COPD.S64135412258025114519Search in Google Scholar

26Ianosi ES, Postolache P, Macovei LA, Szathmary M, Szasz S, Nemes RM, et al. Smoking cessation in COPD patients by a selective partial nicotinic agonist. Revista de Chimie. 2018;69(7): 1766–1769.IanosiESPostolachePMacoveiLASzathmaryMSzaszSNemesRMSmoking cessation in COPD patients by a selective partial nicotinic agonistRevista de Chimie20186971766176910.37358/RC.18.7.6413Search in Google Scholar

27Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA. IL 4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. The Journal of Immunology. 1999;162: 6233–6237.DabbaghKTakeyamaKLeeHMUekiIFLausierJANadelJAIL 4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivoThe Journal of Immunology19991626233623710.4049/jimmunol.162.10.6233Search in Google Scholar